This Article Full Text Full Text (PDF) Perspective on This Article Finasteride and Prostate Cancer: New York Times Article All Versions of this Article: 1940-6207.CAPR-08-0078v1 1940-6207.CAPR-08-0078v2 1940-6207.CAPR-08-0078v3 1/3/167    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lucia, M. S. Articles by Thompson, I. M. Search for Related Content PubMed PubMed Citation Articles by Lucia, M. S. Articles by Thompson, I. M.

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

Authors' Affiliations: ¹ University of Colorado Denver School of Medicine, Aurora, Colorado; ² Fred Hutchinson Cancer Research Center, Seattle, Washington; ³ National Cancer Institute, Bethesda, Maryland; ⁴ Southwest Oncology Group; and ⁵ The University of Texas Health Science Center at San Antonio, San Antonio, Texas

Requests for reprints: M. Scott Lucia, Department of Pathology, University of Colorado Denver, 12800 East 19th Avenue, Mail Stop 8104, Aurora, CO 80045; Phone: 303-724-3470; Fax: 303-724-1427; E-mail: scott.lucia{at}uchsc.edu.

The Prostate Cancer Prevention Trial (PCPT) showed a risk of prostate cancer at prostate-specific antigen (PSA) <4.0 ng/mL and that prostate cancer risk is reduced by finasteride. A major concern about early detection by PSA and prevention by finasteride is that they may involve biologically inconsequential tumors. We reviewed the pathologic characteristics of prostate biopsies from men in the placebo and finasteride groups of the PCPT. We examined tumor pathology characteristics stratified by level of PSA for men in the placebo group who underwent radical prostatectomy. Seventy-five percent of all cancers and 62% of Gleason score 6 cancers in the PCPT met the biopsy criteria for clinically significant tumors. Surrogate measures for tumor volume (number of cores positive, percent cores positive, linear extent, and bilaterality) and risk of perineural invasion were lower in men who received finasteride. The PSA-associated risks of insignificant cancer were 51.7% (PSA, 0-1.0 ng/mL), 33.7% (1.1-2.5 ng/mL), 17.8% (2.6-4.0 ng/mL), and 11.7% (4.1-10 ng/mL). Conversely, the risks of high-grade (Gleason score 7) tumors for the same PSA strata were 15.6%, 37.9%, 49.1%, and 52.4%, respectively. These data highlight the dilemma of PSA when used for screening: Lower cutoff levels increase detection of insignificant disease, but cure is more likely, whereas higher cutoff levels make detection of significant cancer more likely, but cure is less likely. Therefore, the effectiveness of finasteride in preventing prostate cancer, including Gleason score 6 cancer, with meaningful rates of significant disease in the PCPT suggests that cutoff values for PSA screening should be individualized and that men undergoing screening should be informed of the opportunity to reduce their risk of disease with finasteride.

This article has been cited by other articles:

				L. Esserman, Y. Shieh, and I. Thompson Rethinking Screening for Breast Cancer and Prostate Cancer JAMA, October 21, 2009; 302(15): 1685 - 1692. [Abstract] [Full Text] [PDF]

				S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thompson, L. G. Ford, H. L. Parnes, L. M. Minasian, J. M. Gaziano, J. A. Hartline, et al. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA, January 7, 2009; 301(1): 39 - 51. [Abstract] [Full Text] [PDF]

				M. S. Lucia Abstract CN01-02: The Prostate Cancer Prevention Trial: An update on pathology Cancer Prevention Research, November 1, 2008; 1(7_MeetingAbstracts): CN01-02 - CN01-02.